radiology-oncology-2018-scientifictracks

16 / 22

Volume 7 OMICS Journal of Radiology Radiology and Oncology 2018
July 16-17, 2018
Page 48
Notes:
conferenceseries.com
July 16-17, 2018 Dubai, UAE
Radiology and Oncology
2 nd World Congress on
Why oncology field need Biosimilars?
Background: One of the major products in treatment expenditures at oncology field are biological products. Representing
a remarkable percentage of oncology pipeline which increase economic burden on payers and may lead to treatment
restrictions due to high cost of biologicals. Introducing biosimilars products may offer safe, effective, sometimes cost saving
alternative to innovator biological therapies, which may lead to change treatment polices due to different alternatives
represented by biosimilars.
Objective: The main objective is to evaluate introducing biosimilars to the oncology treatment through guidelines
modification, numbers of treated patients, price discounts for innovator products and quality of service introduced to the
patients.
Method: Data analyzed for (113,429) cancer patient for the last 3 years from national database including (treatment
guidelines-patients satisfaction serves-reimbursement lists-price offers for innovator). Local biosimilars guidelines were
the reference for estimating local biosimilars.
Result: Introducing biosimilars products to Egyptian market at last 3 years lead to changing neutropenia guidelines were
modified for including (GCSF as a routine treatment for both prophylactic and after chemotherapy). HER2+ guidelines
modified to contain monoclonal products as a standard of care for both adjuvant and metastatic cases. Monoclonal
antibodies were included at NHL guidelines. Number of treated cancer patients increased by 40% last 3 years. Price
discounts for innovator products were found in values ranged from 35%-66%. Surveys illustrated that patient’s satisfaction
about introducing new products reducing time of treatment for neutropenia patients, hospitalization time decreased due to
modification of neutropenia guidelines.
Conclusion: Introducing biosimilars to the oncology field may lead to offer safe, effective efficient solution for controlling
budget and enhancing health service. Biosimilars may have a major role for achieving perfect computation at oncology field.
Biography
Abdalla Abotaleb, MD is a World Health Organization expert. He is also a consultant on health economics at the Egyptian Ministry of Health, as well as a member
of the Egyptian health care reforming committee Ispor (member, judge and reviewer).
Abdalla Abotaleb
World Health Organization, Egypt
Abdalla Abotaleb, OMICS J Radiol 2018, Volume 7
DOI: 10.4172/2167-7964-C1-021